ImmunOs’ approach is based on insights into autoimmune diseases that are driven by overshooting immune responses. Transferring this mechanism to cancer patients, which are in need of a targeted immune system activation, results in significant changes in the tumor microenvironment and the transformation of a “cold” to a “hot” tumor that can be eliminated by the immune system. 

ImmunOs´ oncology product candidates target several key LILRB receptors via a single molecule – a major differentiation from competitor compounds, which usually only target a single receptor (as antibodies do). Thereby, ImmunOs´ approach can trigger a synergistic response of immune cells leading to anti-tumor responses. 

Background on Cancer Immunotherapy

Background on ImmunOs´ multi-targeting approach for remodeling the tumor microenvironment